The Approval of Redemplo for Familial Chylomicronemia Syndrome and the Many Flavors of GalNAc-Oligonucleotides

In the fourth quarter of 2025, a press release announced the approval of the eighth small interfering RNA (siRNA)-based therapeutic. Redemplo (plozasiran), developed by Arrowhead Pharmaceuticals, is the third oligonucleotide-based medicine approved for the treatment of patients with familial chylomicronemia syndrome targeting apolipoprotein C-III. This approval represents the seventh approved siRNA drug based on GalNAc-mediated hepatocyte delivery and introduces the third distinct flavor of this delivery architecture to the clinic.